Table 5

OR with 95% CI of developing relapsing-onset and progressive-onset MS among subjects categorised by DRB1*15:01 and environmental factors

Interaction between DRB1*15:01 and smoking
Relapsing-onset MSProgressive-onset MS
DRB1*15:01Smokingca/co*aOR (95% CI)†aOR (95% CI)‡ca/co*aOR (95% CI)†aOR (95% CI)‡
1109/25431.0 (reference)1.0 (reference)71/25431.0 (reference)1.0 (reference)
+1478/22481.6 (1.4 to 1.8)1.7 (1.5 to 1.8)132/22481.8 (1.4 to 2.5)2.0 (1.5 to 2.9)
+1626/10023.8 (3.4 to 4.2)3.6 (3.3 to 4.1)96/10023.4 (2.5 to 4.8)3.2 (2.3 to 4.4)
++1896/8905.2 (4.6 to 5.8)5.3 (4.7 to 5.9)157/8905.5 (4.1 to 7.5)6.0 (4.4 to 8.2)
AP0.2 (0.1 to 0.3)0.2 (0.1 to 0.3)0.2 (0.02 to 0.4)0.3 (0.1 to 0.5)
Interaction between DRB1*15:01 and obesity
DRB1*15:01Obesityca/co*aOR (95% CI)†aOR (95% CI)§ca/co*aOR (95% CI)†aOR (95% CI)§
2422/45951.0 (reference)1.0 (reference)187/45951.0 (reference)1.0 (reference)
+66/881.4 (1.0 to 1.9)1.4 (1.0 to 1.9)6/881.7 (0.7 to 4.3)1.6 (0.6 to 4.1)
+3293/18183.5 (3.2 to 3.7)3.4 (3.1 to 3.6)238/18183.2 (2.6 to 4.0)3.1 (2.5 to 3.8)
++118/258.7 (5.6 to 13.4)8.4 (5.4 to 12.9)8/258.0 (3.4 to 18.8)7.4 (2.9 to 17.8)
AP0.6 (0.4 to 0.8)0.5 (0.3 to 0.8)0.5 (0.1 to 1.0)0.5 (0.01 to 1.0)
Interaction between DRB1*15:01 and EBNA-1 antibody levels
DRB1*15:01EBNA-1 IgG levelsca/co*aOR (95% CI)†aOR (95% CI)¶ca/co*aOR (95% CI)†aOR (95% CI)¶
Low510/18361.0 (reference)1.0 (reference)67/18361.0 (reference)1.0 (reference)
High1284/18322.5 (2.2 to 2.9)2.5 (2.2 to 2.8)110/18321.7 (1.2 to 2.3)1.6 (1.2 to 2.2)
+Low446/5902.8 (2.3 to 3.2)2.9 (2.4 to 3.4)51/5902.(1.7 to 3.6)2.4 (1.6 to 3.6)
+High2179/8868.9 (7.9 to 10.1)9.1 (8.0 to 10.3)170/8865.5 (4.1 to 7.5)5.5 (4.1 to 7.5)
AP0.5 (0.4 to 0.6)0.5 (0.4 to 0.6)0.4 (0.3 to 0.6)0.4 (0.3 to 0.6)
Interaction between DRB1*15:01 and sun exposure
Relapsing-onset MS Progressive-onset MS
DRB1*15:01Sun exposureca/co*aOR (95% CI)†aOR (95% CI)**ca/co*aOR (95% CI)†aOR (95% CI)**
High1921/38641.0 (reference)1.0 (reference)155/38641.0 (reference)1.0 (reference)
Low666/9271.4 (1.3 to 1.6)1.4 (1.3 to 1.6)48/9271.2 (0.8 to 1.7)1.1 (0.8 to 1.6)
+High2628/15163.5 (3.2 to 3.8)3.4 (3.1 to 3.7)166/15162.7 (2.2 to 3.5)2.7 (2.1 to 3.4)
+Low894/3764.8 (4.2 to 5.5)4.8 (4.1 to 5.4)87/3765.3 (3.9 to 7.1)4.8 (3.4 to 6.2)
AP0.2 (0.1 to 0.4)0.2 (0.1 to 0.3)0.4 (0.3 to 0.6)0.4 (0.2 to 0.6)
  • *Number of exposed cases and controls.

  • †Adjusted for study, year of enrolment, age, sex, residential area and ancestry.

  • ‡Adjusted for study, year of enrolment, age, sex, residential area, ancestry, obesity, alcohol consumption, sun exposure habits, snuff use, HLA-A*02:01 and EBNA-1 antibody status.

  • §Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, alcohol consumption, sun exposure habits, snuff use, HLA-A*02:01 and EBNA-1 antibody status.

  • ¶Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, obesity, alcohol consumption, sun exposure habits, snuff use and HLA-A*02:01.

  • **Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, obesity, alcohol consumption, snuff use, HLA-A*02:01 and EBNA-1 antibody status.

  • aOR, adjusted OR; AP, Attributable proportion due to interaction; MS, multiple sclerosis.